Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. - Wikidata - wikimedia - TriplyDB

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

http://www.wikidata.org/entity/Q33867651

about

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weigh Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus The pharmacological basis of anti-IgE therapy A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen.Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting.Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2 Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Prolonged urticaria with 17-1A antibody.Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.The emerging role of radioimmunotherapy in haematological malignancies.A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma.Advances in interleukin 2 receptor targeted treatment New approaches to antibody therapy.Development of a humanized antibody with high therapeutic potential against dengue virus type 2 Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice.Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab.Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.Building better monoclonal antibody-based therapeutics.Controlled-release and local delivery of therapeutic antibodies.The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer Drug targeting with monoclonal antibodies. A review.Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice The role of basiliximab induction therapy in organ transplantation.Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.Implications of EGFR PharmDx kit for cetuximab eligibility.A simple methodology for conversion of mouse monoclonal antibody to human-mouse chimeric form.Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.Humanization of murine monoclonal antibodies through variable domain resurfacing.

P2860

Q24561800-8936047F-951E-4CF6-AFBE-C6CD07EE3FA4 Q24645675-1352DF89-A27F-4387-9994-949D8D8A9CDC Q24654724-92119102-3F96-4E71-8B48-3D73CB0B7203 Q27473186-7F58DC1B-157E-48C0-81A5-A11B582764C1 Q28143946-251537B9-39FC-4223-BC52-88F978BE5795 Q30657795-DF34F787-075B-4744-98B1-38BB278726D6 Q31076446-F4C117B5-DEA4-4532-92BB-1EDA0FC84005 Q33641577-2DB83913-C418-4326-9D39-AD53BDAC9CAD Q33685694-4F32311B-A348-45EC-971D-9616D6D01028 Q33712484-CB5A41CC-22AA-437E-8D1C-6548B2AA34AB Q33754371-A6E02BC5-D9F6-429F-8C1B-7231FEB4775E Q33867577-1309C1DD-E2B3-4BD1-8BCF-4EDE228CFC2B Q33880904-6E0129E2-95EE-46E6-8D6C-098330A78648 Q33904384-CCB8B7E3-171A-4EA6-A80A-D61A9B23040A Q33907508-B0CEE53D-D39A-40C9-994D-1BE71A8D04C2 Q34071328-27F23BDC-F403-43D0-B19D-7CF897601D72 Q34130569-7F16BF5D-FC2C-425B-86D3-A53513B6FE06 Q34260219-CB374760-4C41-4C25-A26E-202D687EB42B Q34360666-BA91D4CE-4343-4208-8C41-9D310315F73E Q34451934-6FC0C104-6BB4-4D60-85FD-FFA9D052E6A1 Q34451956-6126AE28-6728-42E1-A3F4-A084F0D2151F Q34536782-A388C07F-013E-4B3B-8FBD-B0A03FE01A8F Q34733916-0B7F4C8E-A48E-4793-9D2F-7C806FC1CD96 Q35049145-1DC5553C-C525-432C-89F8-710596416BB2 Q35060214-39AB2829-080A-448B-8B3D-959E5B25D1CF Q35610243-80B59E49-4334-4FD3-A699-BD52CCD1C380 Q35752167-9078309F-7E34-44B6-9883-12C5B90F4149 Q35817552-FA05EA92-D741-4BEE-8BE7-C5BB53E725F0 Q35842644-D583F2B9-326C-4909-96F6-2E882D45D355 Q35969881-6305F033-C43D-4204-BC1B-18F8D9B1AEAC Q35977304-6BC83514-E08E-4FCA-90C0-18F241E04448 Q36079704-86099CF6-4407-466C-B12D-AE6A5F73723A Q36351254-85F04A64-C50A-4641-8095-B826C0CCA047 Q36476514-59EE5306-8F35-45A8-9676-FECD3C8E47F5 Q36675465-50223F3B-6FCC-4FC3-AF0B-798657433190 Q36752014-189D9FCD-5780-4C26-BF31-34219166D68B Q37118974-09034115-9720-4682-89B5-D602ECFE02B0 Q37178059-9B391E66-50AB-4608-98BC-2B7102DBAA07 Q37457154-8223C558-A7E8-49C8-856D-B3868CE0BF4B Q37558400-56D18E0F-D9EE-4207-88F1-63C272E058B0

P2860

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

http://www.wikidata.org/entity/Q33867651

description

1989 nî lūn-bûn

@nan

1989 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1989 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1989年の論文

@ja

1989年論文

@yue

1989年論文

@zh-hant

1989年論文

@zh-hk

1989年論文

@zh-mo

1989年論文

@zh-tw

1989年论文

@wuu

name

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

@ast

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

@en

type

label

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

@ast

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

@en

prefLabel

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

@ast

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

@en

P1433

Q33867651-C36F8AAE-69D4-431B-B4AB-6631241FBC26

P1476

Q33867651-E6704BDF-6599-4963-BBDA-7E7C51552F3B

P2093

Q33867651-0739E776-C887-4567-B4AB-2FFCDDE460BC

Q33867651-1ACA0FB8-6983-4F56-85E5-7063250A7DF2

Q33867651-254CEB19-7973-4733-B074-893338565AF4

Q33867651-29D01671-AB9F-493D-8EA8-392C737BE756

Q33867651-3CBDF384-8322-45C9-8632-103E09BBC09D

Q33867651-4F532F7A-6746-4A0A-B819-03C71FBC7E7B

Q33867651-DEC89333-C80C-4C66-9C10-F40B28A62128

Q33867651-F45C528C-0C61-4C7B-95E1-95CF32E9F681

Q33867651-F57F8031-7CAA-4416-8033-F7A39308860B

P2860

Q33867651-11D1B3C6-1DD4-481F-91C4-823980E4ED6E

Q33867651-3FAFC7EB-6177-41B3-B0AE-150D7B7C9FF2

Q33867651-8B1C64CF-4699-448E-AEA5-A38B14530420

Q33867651-9AD51477-CBFC-4C6E-AA3D-B065F8854103

Q33867651-C6601EEC-4DFB-40FD-9EC6-67AC6CA9A45C

Q33867651-C7E29B22-5863-438C-A42E-B6A5E427145F

Q33867651-C887C012-1A30-4D86-8D29-90A50568037F

Q33867651-E93ADAB4-91F8-4D4E-ACDA-AD9E8BCE057D

Q33867651-ED4F417B-D620-4352-93CC-FD87D38A58BF

Q33867651-EEE9DC97-337C-4127-8F58-28CD24DB5BB9

P304

Q33867651-D1578864-9960-4CA4-A912-AEC2D077D94B

P31

Q33867651-93E75CE8-973E-4BAD-83B6-3B5DE22B9EC6

P356

Q33867651-5CCE1BCA-46DA-4AC4-BA32-5D1AEC75D4A9

P407

Q33867651-88D65521-7D9E-4B29-9E1A-92C1EF21C483

P433

Q33867651-2856FACD-7C5E-400A-BA2F-0A5613EC0A76

P478

Q33867651-43A8DB65-DB2D-4B4F-A54C-341850796C4F

P577

Q33867651-7D6DB248-9D43-4B01-A269-8EB9A85EF007

P5875

Q33867651-6D897AF7-1A14-40BF-9983-E26C7ED38609

P698

Q33867651-DB6C7884-FF4E-4178-867B-D392CEDC74BE

P921

Q33867651-EF5FE3FF-7A0F-4D27-9DD3-679745C91941

P932

Q33867651-1D41596A-9930-4630-8BD8-F183BE44EE8A

P356

PNAS.86.11.4220

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

@en

P2093

A F LoBuglio

http://www.w3.org/2001/XMLSchema#string

A Haynes

http://www.w3.org/2001/XMLSchema#string

E B Harvey

http://www.w3.org/2001/XMLSchema#string

J Ghrayeb

http://www.w3.org/2001/XMLSchema#string

J Trang

http://www.w3.org/2001/XMLSchema#string

K Rogers

http://www.w3.org/2001/XMLSchema#string

L Sun

http://www.w3.org/2001/XMLSchema#string

M B Khazaeli

http://www.w3.org/2001/XMLSchema#string

R H Wheeler

http://www.w3.org/2001/XMLSchema#string

P2860

Immune thrombocytopenic purpura. Use of a 125I-labeled antihuman IgG monoclonal antibody to quantify platelet-bound IgG.

Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A.

Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.

Metabolic properties of IgG subclasses in man.

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

Current status of antitumor therapy with monoclonal antibodies.

Transfectomas provide novel chimeric antibodies.

A hapten-specific chimaeric IgE antibody with human physiological effector function.

Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.

P304

4220-4224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.86.11.4220

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

1989-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20429007

http://www.w3.org/2001/XMLSchema#string

P698

2726771

http://www.w3.org/2001/XMLSchema#string

P921

P932

287422

http://www.w3.org/2001/XMLSchema#string